High concordance between Hercep test immunohistochemistry and ERBB2 fluorescence in situ hybridization before and after implementation of American Society of clinical oncology/college of American pathology 2007 guidelines

Modern Pathology

Volumn 25, Issue 10, 2012, Pages 1326-1332

  Vergara Lluri, Maria E ^a   Moatamed, Neda A ^a   Hong, Elizabeth ^a   Apple, Sophia K ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

ASCO CAP guidelines; breast cancer; concordance; ERBB2; FISH; HER2; immunohistochemistry

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; BREAST CARCINOMA; CANCER CELL; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HEPCETEST IMMUNOHISTOCHEMISTRY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MEDICAL SOCIETY; PRACTICE GUIDELINE; PRIORITY JOURNAL; SCORING SYSTEM; STAINING; TUMOR GENE; BREAST TUMOR; COMPARATIVE STUDY; FEMALE; GENETICS; LABORATORY DIAGNOSIS; METABOLISM; METHODOLOGY; PAGET NIPPLE DISEASE; PROTO ONCOGENE;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; FEMALE; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; PRACTICE GUIDELINES AS TOPIC; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL;

EID: 84866989871     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2012.93     Document Type: Article

References (27)

1. Press MF, Pike MC, Chazin VR, et al. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res 1993;53:4960-4970. (Pubitemid 23326194)
2. Press MF, Bernstein L, Thomas PA, et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 1997;15:2894-2904. (Pubitemid 27330017)
3. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-182. (Pubitemid 17231334)
4. Coussens L, Yang-Feng TL, Liao YC, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985;230:1132-1139. (Pubitemid 16169997)
5. Akiyama T, Sudo C, Ogawara H, et al. The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science 1986;232: 1644-1646. (Pubitemid 16095607)
6. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792. (Pubitemid 32222155)
7. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-726. (Pubitemid 34111379)
8. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-2648. (Pubitemid 29415219)
9. Konecny G, Pauletti G, Pegram M, et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst 2003;95:142-153. (Pubitemid 36193263)
10. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-145. (Pubitemid 350003059)
11. Jorgensen JT, Moller S, Rasmussen BB, et al. High concordance between two companion diagnostics tests: a concordance study between the HercepTest and the HER2 FISH pharmDx kit. Am J Clin Pathol 2011;136:145-151.
12. Yaziji H, Goldstein LC, Barry TS, et al. HER-2 testing in breast cancer using parallel tissue-based methods. JAMA 2004;291:1972-1977. (Pubitemid 38544278)
13. Lal P, Salazar PA, Hudis CA, et al. HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: a singleinstitution experience of 2279 cases and comparison of dual-color and single-color scoring. Am J Clin Pathol 2004;121:631-636. (Pubitemid 38533994)
14. Dybdal N, Leiberman G, Anderson S, et al. Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab. Breast Cancer Res Treat 2005;93:3-11. (Pubitemid 41355986)
15. Latta EK, Tjan S, Parkes RK, et al. The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast. Mod Pathol 2002;15:1318-1325. (Pubitemid 35463000)
16. Paik S, Bryant J, Tan-Chiu E, et al. Real-world performance of HER2 testing-national surgical adjuvant breast and bowel project experience. J Natl Cancer Inst 2002;94:852-854. (Pubitemid 34705057)
17. Perez EA, Suman VJ, Davidson NE, et al. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol 2006;24:3032-3038. (Pubitemid 46638937)
18. Moatamed NA, Nanjangud G, Pucci R, et al. Effect of ischemic time, fixation time, and fixative type on HER2/neu immunohistochemical and fluorescence in situ hybridization results in breast cancer. Am J Clin Pathol 2011;136:754-761.
19. Apple S, Pucci R, Lowe AC, et al. The effect of delay in fixation, different fixatives, and duration of fixation in estrogen and progesterone receptor results in breast carcinoma. Am J Clin Pathol 2011;135: 592-598.
20. Middleton LP, Price KM, Puig P, et al. Implementation of American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Recommendations in a tertiary care facility increases HER2 immunohistochemistry and fluorescence in situ hybridization concordance and decreases the number of inconclusive cases. Arch Pathol Lab Med 2009;133: 775-780.
21. Atkinson R, Mollerup J, Laenkholm AV, et al. Effects of the change in cutoff values for human epidermal growth factor receptor 2 status by immunohistochemistry and fluorescence in situ hybridization: a study comparing conventional brightfield microscopy, image analysis-assisted microscopy, and interobserver variation. Arch Pathol Lab Med 2011;135:1010-1016.
22. Dowsett M, Procter M, McCaskill-Stevens W, et al. Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial. J Clin Oncol 2009;27:2962-2969.
23. Rasmussen BB, Regan MM, Lykkesfeldt AE, et al. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. Lancet Oncol 2008;9:23-28.
24. Ross JS. Saving lives with accurate HER2 testing. Am J Clin Pathol 2010;134:183-184.
25. Varshney D, Zhou YY, Geller SA, et al. Determination of HER-2 status and chromosome 17 polysomy in breast carcinomas comparing HercepTest and PathVysion FISH assay. Am J Clin Pathol 2004;121:70-77. (Pubitemid 38090156)
26. Slamon D, Pegram M. Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Semin Oncol 2001;28:13-19.
27. Grimm EE, Schmidt RA, Swanson PE, et al. Achieving 95% cross-methodological concordance in HER2 testing: causes and implications of discordant cases. Am J Clin Pathol 2010;134:284-292.